Episode 144: GU Podcast (2020): Immune Checkpoint Inhibitors In RCC

Immune Checkpoint Inhibitors in RCC
At the conclusion of this activity, participants will be able to:
1. Discuss the current immunotherapy options available for the treatment of RCC.
2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC.
3. Identify and manage immune related adverse events.

This educational series is supported by independent educational grants from:

Astellas
AstraZeneca
Bristol Myers Squibb
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Merck
Pfizer, Inc
Sanofi Genzyme
UroGen Pharma, Inc.

CME Available: auau.auanet.org/node/29846